Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by bioAffinity Technologies, Inc.

< Previous 1 2 3 Next >
bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Announces Closing of $4.8 Million Public Offering
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Appoints New Members to Board of Directors
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Reports Second Quarter 2025 Results
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Reports First Quarter 2025 Results
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.